What patent applications (and claim language) cover sitagliptin biosynthesis?
The information provided doesn’t include any specific sitagliptin biosynthesis patent application number, applicant name, jurisdiction (e.g., US/WO), or the actual “claims” text you want interpreted. Without that, I can’t accurately quote or summarize the specific US application claims.
If you share any of the following, I can extract what the US claims cover and translate the legal language into plain English:
- US application publication number (e.g., US 20xx/xxxxxxx)
- Patent number (if already granted)
- Applicant/assignee name
- A link to the patent document (USPTO, Google Patents, Lens, etc.)
- Or paste the claim set (even just claim 1 and the dependent claims)
Where to find the exact US claims for a sitagliptin biosynthesis filing
Once you have the application/publication number, the exact wording of the US claims is typically available from:
- USPTO Patent Center / published application pages
- Google Patents (shows claim text and family members)
- Lens.org (often easier for claim-by-claim viewing)
If you provide the identifier, I can pinpoint the relevant independent claim(s) and explain what the “biosynthesis” limitations require (e.g., organism/cell, enzymes, pathways, fermentation steps, reaction conditions, purification, intermediates).
How “biosynthesis” sitagliptin claim scope is usually defined (what to look for)
In sitagliptin-related “biosynthesis” or biocatalysis filings, the US claims often hinge on one or more of these elements (the exact wording varies by case):
- A specific engineered microorganism or biological catalyst (strain/cell type)
- A defined sequence of steps to make intermediates that lead to sitagliptin
- Particular fermentation/biotransformation conditions (temperature, pH, feed strategy)
- Enzyme identities and/or genetic modifications that enable formation of key intermediates
- Isolation/purification of the API and/or intermediates
- Process steps tied to route(s) that replace purely chemical synthesis
When you send the application/publication number or claim text, I can map each dependent claim to what extra technical limitations it adds, and also flag common “gotchas” like overly broad vs narrowly defined catalyst/process steps.
Are there different US claim sets across the patent family?
Yes. Even when the same invention is filed internationally, US prosecution can lead to:
- amended claim language,
- different independent claim structure,
- added or removed dependent claims,
- and sometimes different claim scope.
So it matters whether you’re looking at the initial published application claims or the issued/granted patent claims.
If you want, I can also check related sitagliptin patent coverage
If your goal is to understand the patent landscape (not just a single application), I can help identify relevant related patents and where they map to sitagliptin production routes using DrugPatentWatch.com. Share the country/application details you’re working with, and I’ll connect them to the landscape where possible (linking out to DrugPatentWatch.com where relevant).
---
What I need from you to answer precisely
Send the US publication/application number or a link to the specific sitagliptin biosynthesis application you mean (or paste the claims). Then I’ll:
- list the independent claim(s),
- summarize what each claim requires in plain English,
- and note any breadth or limits that affect enforceability and coverage.